100 related articles for article (PubMed ID: 33511895)
1. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
Kazerooni R; Watanabe JH
J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
[No Abstract] [Full Text] [Related]
2. Real-world differences in dosing and clinical utilization of OnabotulinumtoxinA and AbobotulinumtoxinA in the treatment of upper limb spasticity.
Bohart Z; Dashtipour K; Kim H; Schwartz M; Zuzek A; Singh R; Nelson M
Toxicon; 2024 Apr; 241():107678. PubMed ID: 38447766
[TBL] [Abstract][Full Text] [Related]
3. Safety and Real-World Dosing of OnabotulinumtoxinA for the Treatment of Adult Spasticity: Post Hoc Analysis of the Adult Spasticity International Registry Study.
Bavikatte G; Esquenazi A; Dimyan MA; Dashtipour K; Feng W; Mayadev A; Fanning K; Musacchio T; Zuzek A; Francisco GE
Am J Phys Med Rehabil; 2024 Jul; 103(7):580-587. PubMed ID: 38206635
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and costs among patients with post-stroke spasticity before and after spasticity management including onabotulinumtoxina.
Esquenazi A; Bloudek L; Migliaccio-Walle K; Oliveri D; Tung A; Gillard P; Verduzco-Gutierrez M
J Rehabil Med; 2023 Oct; 55():jrm11626. PubMed ID: 37902443
[TBL] [Abstract][Full Text] [Related]
5. Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A.
Hernández Herrero D; Miangolarra Page JC
Neurologia (Engl Ed); 2022 Oct; 37(8):653-660. PubMed ID: 31899014
[TBL] [Abstract][Full Text] [Related]
6. AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.
Abogunrin S; Brand S; Desai K; Dinet J; Gabriel S; Harrower T
Clinicoecon Outcomes Res; 2015; 7():441-9. PubMed ID: 26392782
[TBL] [Abstract][Full Text] [Related]
7. Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis.
Molteni F; Wissel J; Fheodoroff K; Munin MC; Patel AT; Althaus M; Comes G; Dekundy A; Pulte I; Scheschonka A; Vacchelli M; Santamato A
Toxins (Basel); 2023 Dec; 16(1):. PubMed ID: 38251237
[TBL] [Abstract][Full Text] [Related]
8. Following the money: factors associated with the cost of treating high-cost Medicare beneficiaries.
Reschovsky JD; Hadley J; Saiontz-Martinez CB; Boukus ER
Health Serv Res; 2011 Aug; 46(4):997-1021. PubMed ID: 21306368
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of botulinum toxin injection on blink rate in blepharospasm.
Yazdanpanah G; Yen MT; Pflugfelder SC
Orbit; 2023 Dec; 42(6):571-578. PubMed ID: 36484152
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions.
Makino K; Mahant N; Tilden D; Aghajanian L
Neurol Ther; 2020 Jun; 9(1):117-133. PubMed ID: 32162214
[TBL] [Abstract][Full Text] [Related]
11. History of Botulinum Toxin Treatment in Movement Disorders.
Jabbari B
Tremor Other Hyperkinet Mov (N Y); 2016; 6():394. PubMed ID: 27917308
[TBL] [Abstract][Full Text] [Related]
12. Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia.
Fernandez HH; Pagan F; Danisi F; Greeley D; Jankovic J; Verma A; Sethi K; Pappert EJ;
Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 23724362
[TBL] [Abstract][Full Text] [Related]
13. Volume and intensity of Medicare physicians' services: an overview.
Kay TL
Health Care Financ Rev; 1990; 11(4):133-46. PubMed ID: 10113398
[TBL] [Abstract][Full Text] [Related]
14. Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations.
Jost WH; Bäumer T; Bevot A; Birkmann U; Buhmann C; Grosheva M; Guntinas-Lichius O; Laskawi R; Paus S; Pflug C; Schroeder AS; Spittau B; Steffen A; Wilken B; Winterholler M; Berweck S
Front Neurol; 2023; 14():1275807. PubMed ID: 38162447
[TBL] [Abstract][Full Text] [Related]
15. 5-Year Follow-Up of a Physician Performance Feedback Report Intervention to Reduce Overuse and Excess Cost: A National Cohort Study.
Dun C; Walsh CM; Hicks CW; Stasko T; Vidimos AT; Leshin B; Billingsley EM; Coldiron BM; Bennett RG; Marks VJ; Otley C; Rogers HW; Goldman GD; Albertini JG; Makary MA
Dermatol Surg; 2024 Jun; 50(6):558-564. PubMed ID: 38578837
[TBL] [Abstract][Full Text] [Related]
16. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs.
Anderson KE; DiStefano MJ; Liu A; Mattingly TJ; Socal MP; Anderson GF
Value Health; 2023 Sep; 26(9):1381-1388. PubMed ID: 37285915
[TBL] [Abstract][Full Text] [Related]
17. Cost Analysis of Oral Phenazopyridine vs Intravesical Lidocaine for Preprocedural Analgesia for Intradetrusor OnabotulinumtoxinA Injections.
Kapur A; Jericevic D; Wang R; Stewart L; Siddique M
Urol Pract; 2024 Jun; ():101097UPJ0000000000000628. PubMed ID: 38913587
[TBL] [Abstract][Full Text] [Related]
18. Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada.
Richer L; Luu H; Martins KJB; Vu K; Guigue A; Wong KO; Nguyen PU; Rajapakse T; Williamson T; Klarenbach SW
Headache; 2023 Oct; 63(9):1285-1294. PubMed ID: 37610171
[TBL] [Abstract][Full Text] [Related]
19. Diffusion of botulinum toxins.
Brodsky MA; Swope DM; Grimes D
Tremor Other Hyperkinet Mov (N Y); 2012; 2():. PubMed ID: 23440162
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
